Semaglutide has been approved by the FDA for use in overweight and obese adults with one or more weight related conditions including high blood pressure, type 2 diabetes and high cholesterol. This new drug is intended as an addition to calorie restricted diet along side exercise routine.
Semaglutide is the generic for other glucagon-like peptide 1 (GLP1) diets such as Wegovy or Ozempic.
Medical Weight Loss
Approximately 70% of American adults are overweight. Having obesity or being overweight is a serious health issue associated with some leading causes of death, including heart disease, stroke and diabetes, and is linked to an increased risk of certain types of cancer. Losing 5% to 10% of body weight through diet, exercise and medical weight loss has been proven to reduce the risk of cardiovascular disease in adult patients with obesity.